Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.

Numerous studies in animal models and more recent studies in humans have demonstrated cancer chemopreventive effects with Se. There is extensive evidence that monomethylated forms of Se are critical metabolites for chemopreventive effects of Se. Induction of apoptosis in transformed cells is an important chemopreventive mechanism. Apoptosis can be triggered by micromolar levels of monomethylated forms of Se independent of DNA damage and in cells having a null p53 phenotype. Cell cycle protein kinase cdk2 and protein kinase C are strongly inhibited by various forms of Se. Inhibitory mechanisms involving modification of cysteine residues in proteins by Se have been proposed that involve formation of Se adducts of the selenotrisulfide (S-Se-S) or selenenylsulfide (S-Se) type or catalysis of disulfide formation. Selenium may facilitate reactions of protein cysteine residues by the transient formation of more reactive S-Se intermediates. A novel chemopreventive mechanism is proposed involving Se catalysis of reversible cysteine/disulfide transformations that occur in a number of redox-regulated proteins, including transcription factors. A time-limited activation mechanism for such proteins, with deactivation facilitated by Se, would allow normalization of critical cellular processes in the early stages of transformation. There is uncertainty at the present time regarding the role of selenoproteins in chemoprevention model systems where supranutritional levels of Se are employed. Mammalian thioredoxin reductase is one selenoprotein that shows increased activity with Se supplementation in the nutritional to supranutritional range. Enhanced thioredoxin reduction could have beneficial effects in oxidative stress, but possible adverse effects are considered. Other functions of thioredoxin reductase may be relevant to cell signaling pathways. The functional status of the thioredoxin/thioredoxin reductase system during in vivo chemoprevention with Se has not been established. Some in vitro studies have shown inhibitory effects of Se on the thioredoxin system correlated with growth inhibition by Se. A potential inactivating mechanism for thioredoxin reductase or other selenoenzymes involving formation of a stable diselenide form resistant to reduction is discussed. New aspects of Se biochemistry and possible functions of new selenoproteins in chemoprevention are described.

[1]  Wei Guo,et al.  A comparative study of the kinetics of selenol/diselenide and thiol/disulfide exchange reactions , 1989 .

[2]  R. Gopalakrishna,et al.  Cancer-preventive selenocompounds induce a specific redox modification of cysteine-rich regions in Ca(2+)-dependent isoenzymes of protein kinase C. , 1997, Archives of biochemistry and biophysics.

[3]  A. Holmgren,et al.  A Pro to His mutation in active site of thioredoxin increases its disulfide-isomerase activity 10-fold. New refolding systems for reduced or randomly oxidized ribonuclease. , 1992, The Journal of biological chemistry.

[4]  T. Stadtman,et al.  Human thioredoxin reductase from HeLa cells: selective alkylation of selenocysteine in the protein inhibits enzyme activity and reduction with NADPH influences affinity to heparin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Mccollum,et al.  Thioredoxin reductase activity is decreased by selenium deficiency. , 1997, Biochemical and biophysical research communications.

[6]  A. Holmgren,et al.  Selenite is a substrate for calf thymus thioredoxin reductase and thioredoxin and elicits a large non-stoichiometric oxidation of NADPH in the presence of oxygen. , 1992, European journal of biochemistry.

[7]  D. Medina,et al.  Selenium distribution in mammary epithelial cells reveals its possible mechanism of inhibition of cell growth. , 1988, Anticancer research.

[8]  H. Ganther,et al.  Activities of structurally-related lipophilic selenium compounds as cancer chemopreventive agents. , 1998, Anticancer research.

[9]  H. Ganther,et al.  Chemical form of selenium, critical metabolites, and cancer prevention. , 1991, Cancer research.

[10]  C. Ip Selenium inhibition of chemical carcinogenesis. , 1985, Federation proceedings.

[11]  G. Powis,et al.  Effect of selenium on rat thioredoxin reductase activity: increase by supranutritional selenium and decrease by selenium deficiency. , 1999, Biochemical pharmacology.

[12]  R. Schirmer,et al.  The mechanism of thioredoxin reductase from human placenta is similar to the mechanisms of lipoamide dehydrogenase and glutathione reductase and is distinct from the mechanism of thioredoxin reductase from Escherichia coli. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Böck,et al.  Cotranslational insertion of selenocysteine into formate dehydrogenase from Escherichia coli directed by a UGA codon. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Elias S. J. Arnér,et al.  Mammalian Thioredoxin Reductase Is Irreversibly Inhibited by Dinitrohalobenzenes by Alkylation of Both the Redox Active Selenocysteine and Its Neighboring Cysteine Residue* , 1998, The Journal of Biological Chemistry.

[15]  V. Gladyshev,et al.  Contrasting patterns of regulation of the antioxidant selenoproteins, thioredoxin reductase, and glutathione peroxidase, in cancer cells. , 1998, Biochemical and biophysical research communications.

[16]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[17]  L. Moroder,et al.  Isomorphous replacement of cystine with selenocystine in endothelin: oxidative refolding, biological and conformational properties of [Sec3,Sec11,Nle7]-endothelin-1. , 1998, Journal of molecular biology.

[18]  G. Whitesides,et al.  Selenols catalyze the interchange reactions of dithiols and disulfides in water , 1991 .

[19]  A. Böck,et al.  The formation of diselenide bridges in proteins by incorporation of selenocysteine residues: biosynthesis and characterization of (Se)2-thioredoxin. , 1994, Biochemistry.

[20]  R. Strange,et al.  Apoptosis in the genesis and prevention of cancer. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  A. Böck,et al.  On the mechanism of selenium tolerance in selenium-accumulating plants. Purification and characterization of a specific selenocysteine methyltransferase from cultured cells of Astragalus bisculatus. , 1996, European journal of biochemistry.

[22]  T. Stadtman,et al.  Heparin-binding properties of selenium-containing thioredoxin reductase from HeLa cells and human lung adenocarcinoma cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Medina,et al.  Organic and inorganic selenium compounds inhibit mouse mammary cell growth in vitro by different cellular pathways. , 1996, Cancer letters.

[24]  Bruce W. Turnbull,et al.  Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled Trial , 1996 .

[25]  B. Demple A Bridge to Control , 1998, Science.

[26]  H. Ganther Reduction of the selenotrisulfide derivative of glutathione to a persulfide analog by glutathione reductase. , 1971, Biochemistry.

[27]  H. Ganther,et al.  Selenotrisulfides. II. Cross-linking of reduced pancreatic ribonuclease with selenium. , 1969, Biochemistry.

[28]  G. Storz,et al.  Activation of the OxyR transcription factor by reversible disulfide bond formation. , 1998, Science.

[29]  T. Scholz,et al.  Selenophosphate synthetase. Enzyme properties and catalytic reaction. , 1994, The Journal of biological chemistry.

[30]  R. Strange,et al.  Differential induction of growth arrest inducible genes by selenium compounds. , 1997, Biochemical pharmacology.

[31]  B. Walzog,et al.  Type I iodothyronine deiodinase activity after high selenium intake, and relations between selenium and iodine metabolism in rats. , 1992, The Journal of nutrition.

[32]  G. Powis,et al.  Mechanisms of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent selenium. , 1997, Cancer research.

[33]  G. Powis,et al.  Cellular thioredoxin reductase activity is regulated by selenium. , 1997, Anticancer research.

[34]  H. Ganther Pathways of Selenium Metabolism Including Respiratory Excretory Products , 1986 .

[35]  R. Shamberger Biochemistry of Selenium , 1983, Biochemistry of the Elements.

[36]  L. Kats,et al.  Catalysis of reduction of disulfide by selenol. , 1995, Analytical biochemistry.

[37]  H. Ganther,et al.  Activity of methylated forms of selenium in cancer prevention. , 1990, Cancer research.

[38]  R. Gronostajski,et al.  Thioltransferase (Glutaredoxin) Reactivates the DNA-binding Activity of Oxidation-inactivated Nuclear Factor I* , 1998, The Journal of Biological Chemistry.

[39]  M. Kunkel,et al.  Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. , 1998, Biochemical pharmacology.

[40]  H. Ganther,et al.  Selenium: biochemical role as a component of glutathione peroxidase. , 2009, Science.

[41]  Hsieh Hs,et al.  Acid-volatile selenium formation catalyzed by glutathione reductase. , 1975 .

[42]  D. Kirkpatrick,et al.  Thioredoxin redox control of cell growth and death and the effects of inhibitors. , 1998, Chemico-biological interactions.

[43]  L. Scorrano,et al.  The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. , 1994, The Journal of biological chemistry.

[44]  H. Ganther,et al.  Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage. , 1992, Biochemical pharmacology.

[45]  A. Holmgren,et al.  Selenodiglutathione is a highly efficient oxidant of reduced thioredoxin and a substrate for mammalian thioredoxin reductase. , 1992, The Journal of biological chemistry.

[46]  A. Wendel,et al.  Selenium and drug metabolism--II. Independence of glutathione peroxidase and reversibility of hepatic enzyme modulations in deficient mice. , 1984, Biochemical pharmacology.

[47]  O. Hayaishi,et al.  Inhibition of rat brain prostaglandin D synthase by inorganic selenocompounds. , 1991, Archives of biochemistry and biophysics.

[48]  Cheng Jiang,et al.  Dissociation of the genotoxic and growth inhibitory effects of selenium. , 1995, Biochemical pharmacology.

[49]  R. Schirmer,et al.  The 58 kDa mouse selenoprotein is a BCNU‐sensitive thioredoxin reductase , 1997, FEBS letters.

[50]  Horst Kessler,et al.  The Redox Potential of Selenocystine in Unconstrained Cyclic Peptides , 1997 .

[51]  D. Medina,et al.  Mechanisms of Selenium Inhibition of Tumorigenesis , 1986, Advances in experimental medicine and biology.

[52]  A. Wendel,et al.  Selenium and drug metabolism--I. Multiple modulations of mouse liver enzymes. , 1983, Biochemical pharmacology.

[53]  D. Medina,et al.  Inhibition of cdk2 kinase activity by methylselenocysteine in synchronized mouse mammary epithelial tumor cells. , 1997, Carcinogenesis.

[54]  A. Wendel,et al.  Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. , 1993, The Journal of biological chemistry.

[55]  J. Wootton,et al.  A New Human Selenium-containing Protein , 1998, The Journal of Biological Chemistry.

[56]  C. C. Clayton,et al.  Diet and azo dye tumors; effect of diet during a period when the dye is not fed. , 1949, Cancer research.

[57]  C. Ip,et al.  Lessons from basic research in selenium and cancer prevention. , 1998, The Journal of nutrition.

[58]  T. Stadtman,et al.  Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[59]  N. Vermeulen,et al.  Comparative cytotoxicity of 14 novel selenocysteine se-conjugates in rat renal proximal tubular cells. , 1996, Toxicology and applied pharmacology.

[60]  D. Medina,et al.  Current ideas on selenium as a chemopreventive agent. , 1988, Pathology and immunopathology research.

[61]  M. Szyf,et al.  A mammalian protein with specific demethylase activity for mCpG DNA , 1999, Nature.

[62]  T. Brüning,et al.  Selenium-mediated inhibition of transcription factor NF-κ B and HIV-1 LTR promoter activity , 1996, Archives of Toxicology.

[63]  Elias S. J. Arnér,et al.  Rat and Calf Thioredoxin Reductase Are Homologous to Glutathione Reductase with a Carboxyl-terminal Elongation Containing a Conserved Catalytically Active Penultimate Selenocysteine Residue* , 1998, The Journal of Biological Chemistry.

[64]  D. Medina,et al.  Intracellular 58-kd selenoprotein levels correlate with inhibition of DNA synthesis in mammary epithelial cells. , 1988, Carcinogenesis.

[65]  H. Ganther,et al.  Acid-volatile selenium formation catalyzed by glutathione reductase. , 1975, Biochemistry.

[66]  C. Jiang,et al.  Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. , 1994, Biochemical pharmacology.

[67]  L. Hevesi,et al.  Organoselenium Chemistry I , 1988 .

[68]  A. Wendel,et al.  Selenium and drug metabolism--III. Relation of glutathione-peroxidase and other hepatic enzyme modulations to dietary supplements. , 1985, Biochemical pharmacology.

[69]  G. Mccollum,et al.  Determination of thioredoxin reductase activity in rat liver supernatant. , 1997, Analytical biochemistry.

[70]  G. Spyrou,et al.  AP‐1 DNA‐binding activity is inhibited by selenite and selenodiglutathione , 1995, FEBS letters.

[71]  A. Holmgren,et al.  Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. , 1993, Biochemistry.

[72]  V. Gladyshev,et al.  Redox Regulation of Cell Signaling by Selenocysteine in Mammalian Thioredoxin Reductases* , 1999, The Journal of Biological Chemistry.

[73]  D. Medina,et al.  Significance of selenium-labeled proteins for selenium's chemopreventive functions. , 1993, Carcinogenesis.

[74]  A. Wendel,et al.  Alterations in the intermediary metabolism of selenium-deficient mice. , 1987, Biochimica et biophysica acta.

[75]  S. Nanduri,et al.  Reactivity of the human thioltransferase (glutaredoxin) C7S, C25S, C78S, C82S mutant and NMR solution structure of its glutathionyl mixed disulfide intermediate reflect catalytic specificity. , 1998, Biochemistry.

[76]  H. Ganther,et al.  Chemical transformations of selenium in living organisms. Improved forms of selenium for cancer prevention , 1997 .

[77]  G. Combs,et al.  Chemopreventive agents: selenium. , 1998, Pharmacology & therapeutics.

[78]  T. Stadtman,et al.  A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[79]  J. Tyson,et al.  Analytical selenoamino acid studies by chromatography with interfaced atomic mass spectrometry and atomic emission spectral detection , 1998 .

[80]  R. Burk Biological activity of selenium. , 1983, Annual review of nutrition.

[81]  R. Burk,et al.  Dietary selenium intake controls rat plasma selenoprotein P concentration. , 1989, The Journal of nutrition.

[82]  W. Maret,et al.  Selenium redox biochemistry of zinc-sulfur coordination sites in proteins and enzymes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.